Efficacy and Safety of Pertuzumab and Trastuzumab Administered in a Single Infusion Bag, Followed by Vinorelbine: VELVET Cohort 2 Final Results

Michael Andersson, José M López-Vega, Thierry Petit, Claudio Zamagni, Valerie Easton, Julia Kamber, Eleonora Restuccia, Edith A Perez, Michael Andersson, José M López-Vega, Thierry Petit, Claudio Zamagni, Valerie Easton, Julia Kamber, Eleonora Restuccia, Edith A Perez

Abstract

Background: VELVET Cohort 1 demonstrated the applicability of pertuzumab, trastuzumab, and vinorelbine as an alternative first-line treatment regimen for patients with HER2-positive locally advanced or metastatic breast cancer (MBC) who cannot receive docetaxel. Co-infusion of pertuzumab and trastuzumab may reduce clinic time and medical resource utilization. We report results from Cohort 2, in which pertuzumab and trastuzumab were co-infused, followed by vinorelbine.

Patients and methods: During cycle 1, patients with HER2-positive locally advanced or MBC received loading doses of pertuzumab (840 mg) and trastuzumab (8 mg/kg) on consecutive days, followed by vinorelbine (25 mg/m2) on days two and nine. From cycle 2 onwards, patients received a co-infusion of pertuzumab (420 mg) and trastuzumab (6 mg/kg) on day one, followed by vinorelbine (30-35 mg/m2) on days one and eight (or days two and nine). The primary endpoint was objective response rate (ORR) in patients with measurable disease. Secondary endpoints included progression-free survival (PFS) and safety.

Results: Cohort 2 enrolled 107 patients. The ORR was 63.7% (95% confidence interval [CI] 53.0-73.6) in patients with measurable disease (91/107; 85.0%). Median PFS was 11.5 months (95% CI 10.3-15.8). The most common adverse events [AEs] were diarrhea (57.9%), neutropenia (57.0%), and nausea (41.1%). Grade ≥3 AEs occurred in 85 patients (79.4%) and serious AEs in 44 patients (41.1%). Eighteen patients (16.8%) had AEs suggestive of congestive heart failure.

Conclusion: These results support the feasibility of pertuzumab and trastuzumab co-infusion from a safety perspective and support Cohort 1 conclusions that vinorelbine offers an alternative chemotherapy companion for pertuzumab and trastuzumab. The Oncologist 2017;22:1160-1168 IMPLICATIONS FOR PRACTICE: Combined treatment with pertuzumab, trastuzumab, and docetaxel is the standard of care for first-line HER2-positive metastatic breast cancer. However, some patients cannot, or choose not to, receive docetaxel. VELVET Cohort 2 results support the results from Cohort 1 that suggest that pertuzumab plus trastuzumab and vinorelbine is a suitable alternative for these patients. In addition to this, results from Cohort 2 support the feasibility of administering pertuzumab and trastuzumab together in a single infusion bag, which has the potential to offer greater patient convenience and reduce active health care professional time and medical resource utilization compared with administering them separately.

Keywords: HER2-positive; Metastatic breast cancer; Pertuzumab; Trastuzumab; Vinorelbine.

Conflict of interest statement

Disclosures of potential conflicts of interest may be found at the end of this article.

© 2017 The Authors. The Oncologist published by Wiley Periodicals, Inc. on behalf of AlphaMed Press.

Figures

Figure 1.
Figure 1.
Planned maximum infusion times for combined versus sequential pertuzumab and trastuzumab infusion. Pertuzumab and trastuzumab were given as sequential infusions in cycle 1 of Cohort 1 and Cohort 2. In Cohort 1, pertuzumab and trastuzumab were given as sequential infusions from cycle 2 onwards; in Cohort 2, pertuzumab and trastuzumab were given as a co‐infusion from cycle 2 onwards. aPertuzumab time was 0.5–1 hour; maximum time is shown [15], [16], [17].
Figure 2.
Figure 2.
VELVET Cohort 2 study profile. aThe 15 patients ongoing with any study treatment at time of study closure are also counted under administrative/other reasons. Abbreviation: ITT, intent‐to‐treat.
Figure 3.
Figure 3.
Progression‐free survival (intent‐to‐treat population). Abbreviation: CI, confidence interval.

References

    1. Giordano SH, Temin S, Kirshner JJ et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2‐positive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2014;32:2078–2099.
    1. Cardoso F, Costa A, Norton L et al. ESO‐ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast 2014;23:489–502.
    1. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Gastric Cancer. Version 3. 2016. Available at . Accessed August, 2016.
    1. Baselga J, Cortés J, Kim SB et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366:109–119.
    1. Swain SM, Baselga J, Kim SB et al. Pertuzumab, trastuzumab, and docetaxel in HER2‐positive metastatic breast cancer. N Engl J Med 2015;372:724–734.
    1. Glover ZW, Gennaro L, Yadav S et al. Compatibility and stability of pertuzumab and trastuzumab admixtures in i.v. infusion bags for coadministration. J Pharm Sci 2013;102:794–812.
    1. Peréz EA, López‐Vega JM, Petit T et al. Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first‐line treatment of patients with HER2‐positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results. Breast Cancer Res 2016;18:126.
    1. Andersson M, Lidbrink E, Bjerre K et al. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first‐line therapy of metastatic or locally advanced human epidermal growth factor receptor 2‐positive breast cancer: The HERNATA study. J Clin Oncol 2011;29:264–271.
    1. Ismael G, Hegg R, Muehlbauer S et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2‐positive, clinical stage I‐III breast cancer (HannaH study): A phase 3, open‐label, multicentre randomised trial. Lancet Oncol 2012;13:869–878.
    1. Launay‐Vacher V. An appraisal of subcutaneous trastuzumab: A new formulation meeting clinical needs. Cancer Chemother Pharmacol 2013;72:1361–1367.
    1. Pivot X, Gligorov J, Müller V et al. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2‐positive early breast cancer (PrefHer): An open‐label randomised study. Lancet Oncol 2013;14:962–970.
    1. Pivot X, Gligorov J, Müller V et al. Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2‐positive early breast cancer: Final analysis of 488 patients in the international, randomized, two‐cohort PrefHer study. Ann Oncol 2014;25:1979–1987.
    1. De Cock E, Pivot X, Hauser N et al. A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2‐positive early breast cancer. Cancer Med 2016;5:389–397.
    1. European Medicines Agency. Herceptin SC Summary of Product Characteristics. . Accessed March, 2016.
    1. Andersson M, López‐Vega JM, Petit T et al. The co‐administration of pertuzumab (P) and trastuzumab (T) as a single infusion, followed by vinorelbine (V), in first‐line (1L) treatment of HER2‐positive locally advanced or metastatic breast cancer (MBC) patients (pts): VELVET study interim analysis. J Clin Oncol 2015;33(suppl abstr 586).
    1. Herceptin® (trastuzumab). Summary of Product Characteristics. Roche Registration Ltd. Available at . Accessed September, 2016.
    1. PERJETA® (pertuzumab). Summary of Product Characteristics. Roche Registration Ltd. Available at . Accessed August, 2016.
    1. Chan A, Delaloge S, Holmes FA et al. Neratinib after trastuzumab‐based adjuvant therapy in patients with HER2‐positive breast cancer (ExteNET): A multicentre, randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Oncol 2016;17:367–377.
    1. Wolff AC, Hammond ME, Hicks DG et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013;31:3997–4013.
    1. Vinorelbine. Summary of Product Characteristics. Actavis UK Ltd. Available at . Accessed August, 2016.
    1. Lenihan D, Suter T, Brammer M et al. Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. Ann Oncol 2012;23:791–800.
    1. Swain SM, Ewer MS, Cortés J et al. Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2‐positive metastatic breast cancer in CLEOPATRA: A randomized, double‐blind, placebo‐controlled phase III study. The Oncologist 2013;18:257–264.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit